|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 5/09/16 Opko Health, Inc. 10-Q 3/31/16 77:8.6M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 593K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 41K
13: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 105K
14: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 31K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 91K
(Unaudited)
16: R5 Condensed Consolidated Statements of Comprehensive HTML 44K
Loss (Unaudited)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 134K
(Unaudited)
18: R7 Condensed Consolidated Statements of Cash Flows HTML 25K
(Unaudited) (Parenthetical)
19: R8 Business and Organization HTML 33K
20: R9 Summary of Significant Accounting Policies HTML 76K
21: R10 Earnings (Loss) Per Share HTML 29K
22: R11 Composition of Certain Financial Statement HTML 130K
Captions
23: R12 Acquisitions, Investments and Licenses HTML 116K
24: R13 Debt HTML 131K
25: R14 Accumulated Other Comprehensive Income (Loss) HTML 38K
26: R15 Fair Value Measurements HTML 145K
27: R16 Derivative Contracts HTML 53K
28: R17 Related Party Transactions HTML 32K
29: R18 Commitments and Contingencies HTML 36K
30: R19 Strategic Alliances HTML 43K
31: R20 Segments HTML 104K
32: R21 Subsequent Events HTML 34K
33: R22 Summary of Significant Accounting Policies HTML 132K
(Policies)
34: R23 Composition of Certain Financial Statement HTML 131K
Captions (Tables)
35: R24 Acquisitions, Investments and Licenses (Tables) HTML 90K
36: R25 Debt (Tables) HTML 114K
37: R26 Accumulated Other Comprehensive Income (Loss) HTML 35K
(Tables)
38: R27 Fair Value Measurements (Tables) HTML 143K
39: R28 Derivative Contracts (Tables) HTML 48K
40: R29 Segments (Tables) HTML 97K
41: R30 Business and Organization (Details) HTML 48K
42: R31 Summary of Significant Accounting Policies HTML 97K
(Details)
43: R32 Earnings (Loss) Per Share (Details) HTML 34K
44: R33 Composition of Certain Financial Statement HTML 143K
Captions (Details)
45: R34 Composition of Certain Financial Statement HTML 61K
Captions - Changes in Goodwill (Details)
46: R35 Acquisitions, Investments and Licenses - HTML 78K
Acquisition Narrative (Details)
47: R36 Acquisitions, Investments and Licenses - HTML 84K
Bio-Reference Purchase Price Allocation (Details)
48: R37 Acquisitions, Investments and Licenses - Schedule HTML 32K
of Pro Forma (Details)
49: R38 Acquisitions, Investments and Licenses - EirGen HTML 63K
Purchase Price Allocation (Details)
50: R39 Acquisitions, Investments and Licenses - Summary HTML 36K
of Investments (Details)
51: R40 Acquisitions, Investments and Licenses - Equity HTML 52K
Method Investments Narrative (Details)
52: R41 Acquisitions, Investments and Licenses - Available HTML 47K
for Sale Investments, Sale of Investments and
Warrants and Options Narrative (Details)
53: R42 Acquisitions, Investments and Licenses - Variable HTML 60K
Interest Entities Narrative (Details)
54: R43 Acquisitions, Investments and Licenses - Other HTML 49K
Narrative (Details)
55: R44 Debt - Narrative (Details) HTML 144K
56: R45 Debt - Notes (Details) HTML 58K
57: R46 Debt - Inputs Used In Lattice Model (Details) HTML 41K
58: R47 Debt - Fair Value Of Embedded Derivatives HTML 29K
(Details)
59: R48 Debt - Lines Of Credit (Details) HTML 60K
60: R49 Debt - Mortgage Notes And Other Debt (Details) HTML 32K
61: R50 Accumulated Other Comprehensive Income (Loss) HTML 37K
(Details)
62: R51 Fair Value Measurements - Summary Of Investments HTML 36K
(Details)
63: R52 Fair Value Measurements - Assets And Liabilities HTML 60K
Measured At Fair Value (Details)
64: R53 Fair Value Measurements - Notes (Details) HTML 29K
65: R54 Fair Value Measurements - Level 3 Reconciliation HTML 38K
(Details)
66: R55 Fair Value Measurements - Narrative (Details) HTML 34K
67: R56 Derivative Contracts - Balance Sheet Component HTML 40K
(Details)
68: R57 Derivative Contracts - Derivative Gains (Losses) HTML 32K
(Details)
69: R58 Related Party Transactions (Details) HTML 111K
70: R59 Commitments and Contingencies (Details) HTML 37K
71: R60 Strategic Alliances (Details) HTML 96K
72: R61 Segments - Narrative (Details) HTML 42K
73: R62 Segments - Operations and Assets Information HTML 74K
(Details)
74: R63 Subsequent Events (Details) HTML 63K
76: XML IDEA XML File -- Filing Summary XML 136K
75: EXCEL IDEA Workbook of Financial Reports XLSX 108K
6: EX-101.INS XBRL Instance -- opk-20160331 XML 2.50M
8: EX-101.CAL XBRL Calculations -- opk-20160331_cal XML 234K
9: EX-101.DEF XBRL Definitions -- opk-20160331_def XML 1.06M
10: EX-101.LAB XBRL Labels -- opk-20160331_lab XML 2.02M
11: EX-101.PRE XBRL Presentations -- opk-20160331_pre XML 1.28M
7: EX-101.SCH XBRL Schema -- opk-20160331 XSD 190K
77: ZIP XBRL Zipped Folder -- 0000944809-16-000022-xbrl Zip 296K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
May 9, 2016 | /s/ Adam Logal |
Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/9/16 | 8-K | ||
| For Period end: | 3/31/16 | 4 | ||
| List all Filings | ||||